Unbiased antigen platform Impact Proteomics operates an immune-profiling platform that supports known and novel antigen discovery, presenting a potential sales angle to pharmaceutical and academic customers seeking rapid immune target identification and therapeutic development capabilities.

Proteomics and multiomics Their services extend beyond discovery to proteomic and multiomic sample preparation (protein, DNA, RNA, metabolites), offering cross-selling opportunities to labs needing integrated sample prep workflows for comprehensive omics analyses.

NSF-backed validation A recent NSF SBIR Phase II grant underscores credibility and innovation in their ProMTag technology, which can be leveraged in outbound conversations to validate technology maturity and potential for grant-aligned collaborations.

BV and market fit With revenue in the low to mid single digits and a focused niche in autoimmune and cancer diagnostics and therapeutics, there is a clear path to cross-sell analytical services, assay development, and collaborator-driven R&D programs to biotech and academic customers.

Growth through partnerships Small team size suggests high flexibility and potential for strategic collaborations with larger CROs or instrument vendors, enabling joint service offerings, co-marketing, and expanded reach into pharma pipelines.